文献速递心力衰竭与心肌病血脂与心血管预防

心脏移植排斥中肝脏通过PCSK9/CD36通路调控免疫

Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.
PubMed 文献 · Circulation · 2023-05-26

该研究探讨了肝脏分泌的PCSK9在心脏移植排斥中的作用及机制。小鼠和人类受体在排斥期间血清PCSK9升高,PCSK9敲除可延长移植物存活并减少炎症浸润。机制上,TNF-α和IFN-γ通过SREBP2促进肝细胞PCSK9表达,PCSK9抑制巨噬细胞CD36表达和脂肪酸摄取,增强促炎表型,进而促进供体反应性T细胞增殖和IFN-γ产生。

要点

  • 心脏移植排斥期间受体血清PCSK9水平升高。
  • PCSK9敲除可延长心脏移植物存活并减轻炎症。
  • PCSK9通过抑制巨噬细胞CD36增强促炎表型。

核心结论

  • 肝脏通过PCSK9/CD36通路调控心脏移植排斥中的免疫反应,该通路可能成为预防排斥的治疗靶点。

研究设计与样本

  • 研究评估了小鼠和人类受体在心脏移植排斥期间的血清PCSK9表达,并使用全局敲除小鼠和中和抗体研究PCSK9缺失的影响,进行了多器官组织学和转录组分析、肝脏多组学和单细胞RNA测序,以及肝细胞特异性Pcsk9敲除小鼠实验,并在体外和体内探索了PCSK9/CD36通路对巨噬细胞表型和功能的调控。

主要发现

  • 小鼠和人类受体在心脏移植排斥期间血清PCSK9水平高。
  • PCSK9缺失延长了心脏同种异体移植物存活,并减弱了移植物中炎症细胞浸润和脾脏中同种反应性T细胞的扩增。
  • PCSK9主要在受体肝脏中产生并显著上调,肝脏还显示出一系列信号变化,包括TNF-α和IFN-γ信号通路以及胆汁酸和脂肪酸代谢通路的改变。
  • TNF-α和IFN-γ通过转录因子SREBP2协同促进肝细胞中PCSK9表达。
  • PCSK9抑制巨噬细胞CD36表达和脂肪酸摄取,增强促炎表型,从而促进其促进供体反应性T细胞增殖和IFN-γ产生的能力。

临床怎么用

  • 调节PCSK9/CD36通路可能成为预防心脏移植排斥的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin 9), which is mainly secreted by the liver, is not only a therapeutic target for hyperlipidemia and cardiovascular disease, but also has been implicated in the immune regulation of infections and tumors. However, the role of PCSK9 and the liver in heart transplant rejection (HTR) and the underlying mechanisms remain unclear. METHODS: We assessed serum PCSK9 expression in both murine and human recipients during HTR and investigated the effect of PCSK9 ablation on HTR by using global knockout mice and a neutralizing antibody. Moreover, we performed multiorgan histological and transcriptome analyses, and multiomics and single-cell RNA-sequencing studies of the liver during HTR, as well. We further used hepatocyte-specific Pcsk9 knockout mice to investigate whether the liver regulated HTR through PCSK9. Last, we explored the regulatory effect of the PCSK9/CD36 pathway on the phenotype and function of macrophages in vitro and in vivo. RESULTS: Here, we report that murine and human recipients have high serum PCSK9 levels during HTR. PCSK9 ablation prolonged cardiac allograft survival and attenuated the infiltration of inflammatory cells in the graft and the expansion of alloreactive T cells in the spleen. Next, we demonstrated that PCSK9 was mainly produced and significantly upregulated in the recipient liver, which also showed a series of signaling changes, including changes in the TNF-α (tumor necrosis factor α) and IFN-γ (interferon γ) signaling pathways and the bile acid and fatty acid metabolism pathways. We found mechanistically that TNF-α and IFN-γ synergistically promoted PCSK9 expression in hepatocytes through the transcription factor SREBP2 (sterol regulatory element binding protein 2). Moreover, in vitro and in vivo studies indicated that PCSK9 inhibited CD36 expression and fatty acid uptake by macrophages and strengthened the proinflammatory phenotype, which facilitated their ability to promote proliferation and IFN-γ production by donor-reactive T cells. Last, we found that the protective effect of PCSK9 ablation against HTR is dependent on the CD36 pathway in the recipient. CONCLUSIONS: This study reveals a novel mechanism for immune regulation by the liver through the PCSK9/CD36 pathway during HTR, which influences the phenotype and function of macrophages and suggests that the modulation of this pathway may be a potential therapeutic target to prevent HTR.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhang X, Xu H, Yu J, et al. Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection. Circulation. 2023. PMID: 37232170. doi:10.1161/CIRCULATIONAHA.123.062788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。